title: Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bennett
authors.forename: Cara
authors.initials: C
authors.lastname: Angelotta
authors.forename: Paul R
authors.initials: PR
authors.lastname: Yarnold
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Evens
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Zonder
authors.forename: Dennis W
authors.initials: DW
authors.lastname: Raisch
authors.forename: Paul
authors.initials: P
authors.lastname: Richardson
mesh_terms: D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy; D013792:Thalidomide / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013923:Thromboembolism / Q000139:chemically induced* / Q000453:epidemiology
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide